Finance entity
All 1 tracked stories fall under one category: earnings. Inpefa is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 6.2. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline.
Last mentioned: Mar 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. Inpefa is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 6.2. Source depth averages 2 original sources per story, versus 2.6 across the same-window beat baseline. We currently track 1 Finance story that mention Lexicon Pharmaceuticals, all published on March 4, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 74 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Lexicon Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Investors are bracing for Q4 2025 results from Lexicon Pharmaceuticals and Ituran Location, two small-cap players facing critical operational milestones. While Lexicon seeks to prove the commercial viability of its heart failure treatment, Ituran aims to capitalize on expanding telematics demand in emerging markets.
Lexicon Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
